









































~~We claim:~~CLAIMS













1. An oral dosage form comprising a compound selected from:













	
	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	
	
	











	
	
	
	
	
	












	
	
	
	
	
	











	
	
	
	
	













	
	
	
	
	


	
	
	
	
	


	
	
	
	
	





, or a pharmaceutically acceptable salt or prodrug thereof; and
a pharmaceutically acceptable carrier.

2. The oral dosage form of claim 1, comprising about 1 mg to about 1500 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

3. The oral dosage form of claim 1, comprising about 1 mg to about 1200 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

4. The oral dosage form of claim 1, comprising about 1 mg to about 1000 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

5. The oral dosage form of claim 1, comprising about 1 mg to about 800 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

6. The oral dosage form of claim 1, comprising about 1 mg to about 600 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

7. The oral dosage form of claim 1, comprising about 1 mg to about 400 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

8. The oral dosage form of claim 1, comprising about 1 mg to about 300 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

9. The oral dosage form of claim 1, comprising about 1 mg to about 200 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

10. The oral dosage form of claim 1, comprising about 1 mg to about 100 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

11. The oral dosage form of claim 1, comprising about 10 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

12. The oral dosage form of claim 1, comprising about 30 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

13. The oral dosage form of claim 1, comprising about 100 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

14. The oral dosage form of claim 1, comprising about 200 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

15. The oral dosage form of claim 1, comprising about 300 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

16. The oral dosage form of claim 1, comprising about 400 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

17. The oral dosage form of claim 1, comprising about 600 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

18. The oral dosage form of claim 1, comprising about 800 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

19. The oral dosage form of claim 1, comprising about 1000 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.


20. The oral dosage form of claim 1, comprising about 1200 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.











21. The oral dosage form of any one of claims 1-20, wherein the oral dosage form is a capsule.











22. The oral dosage form of any one of claims 1-20, wherein the oral dosage form is a tablet.













23. The oral dosage form of claim 22, wherein the tablet is a coated tablet.













24. Use of ~~A method of treating or preventing a disease or condition characterized by aberrant complement system activity, comprising orally administering to a patient in need thereof~~ a therapeutically effective amount of a compound selected from:

























	
	
	
	
	











	
	
	
	
	











	
	
	
	
	
	











	
	
	
	
	
	












	
	
	
	
	
	











	
	
	
	
	













	
	
	
	
	


	
	
	
	
	



, or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for treating or preventing a disease or condition characterized by aberrant complement system activity, wherein the medicament is to be orally administered to a patient.

25. The use~~method~~ of claim 24, wherein the disease or condition characterized by aberrant complement system activity is an immunological disorder.

26. The use~~method~~ of claim 24, wherein the disease or condition characterized by aberrant complement system activity is a disease of the central nervous system.

27. The use~~method~~ of claim 24, wherein the disease or condition characterized by aberrant complement system activity is a neurodegenerative disease or neurological disease.

28. The use~~method~~ of claim 24, wherein the disease or condition characterized by aberrant complement system activity is a renal disease.

29. The use~~method~~ of claim 24, wherein the disease or condition characterized by aberrant complement system activity is a cardiovascular disease.

30. The use~~method~~ of claim 24, wherein the disease or condition characterized by aberrant complement system activity is selected from the group consisting of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), warm autoimmune hemolytic anemia, IgA nephropathy, C3 glomerulonephritis, and focal segmental glomerulosclerosis.

31. The use~~method~~ of claim 24, wherein the disease or condition characterized by aberrant complement system activity is a hematological disorder.

32. The use~~method~~ of claim 24, wherein the disease or condition characterized by aberrant complement system activity is an ocular disorder or an eye disorder.

33. The use~~method~~ of claim 24, wherein the disease or condition characterized by aberrant complement system activity is macular degeneration, age-related macular degeneration (AMD), macular edema, diabetic macular edema, choroidal neovascularization (CNV), uveitis, Behcet's uveitis, proliferative diabetic retinopathy, non-proliferative diabetic retinopathy, glaucoma, hypertensive retinopathy, a corneal neovascularization disease, post-corneal transplant rejection, a corneal dystrophic disease, an autoimmune dry eye disease, Stevens-Johnson syndrome, Sjogren's syndrome, an environmental dry eye disease, Fuchs' endothelial dystrophy, retinal vein occlusion, or post-operative inflammation.

34. The use~~method~~ of claim 24, wherein the disease or condition characterized by aberrant complement system activity is selected from the group consisting of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome, organ transplant rejection, myasthenia gravis, neuromyelitis optica, membranoproliferative glomerulonephritis, dense-deposit disease, cold agglutinin disease, and catastrophic antiphospholipid syndrome.

35. The use~~method~~ of claim 34, wherein the disease is PNH.

36. The use~~method~~ of claim 35, wherein the PNH is characterized by one or more of hemolytic anemia, thrombosis, and impaired bone marrow function.

37. The use~~method~~ of any one of claims 34-36, wherein the medicament to be orally administered ~~orally administering~~ suppresses hemolysis of erythrocytes or blocks C3 fragment deposition on erythrocytes or both.

38. The use~~method~~ of claim 37, wherein the suppression is greater than or equal to about 50%.

39. The use~~method~~ of claim 37, wherein the suppression is greater than or equal to about 80%.

40. The use~~method~~ of claim 37, wherein the suppression is greater than or equal to about 90%.

41. The use~~method~~ of claim 37, wherein the suppression is greater than or equal to about 95%.

42. The use~~method~~ of any one of claims 24-41, wherein the therapeutically effective amount is about 1 mg to about 1500 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

43. The use~~method~~ of claim 42, wherein the therapeutically effective amount is about 1 mg to about 1200 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

44. The use~~method~~ of claim 42, wherein the therapeutically effective amount is about 1 to about 1000 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

45. The use~~method~~ of claim 42, wherein the therapeutically effective amount is about 1 to about 800 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

46. The use~~method~~ of claim 42, wherein the therapeutically effective amount is about 1 to about 600 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

47. The use~~method~~ of claim 42, wherein the therapeutically effective amount is about 1 to about 400 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

48. The use~~method~~ of claim 42, wherein the therapeutically effective amount is about 1 to about 300 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

49. The use~~method~~ of claim 42, wherein the therapeutically effective amount is about 1 to about 200 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

50. The use~~method~~ of claim 42, wherein the therapeutically effective amount is about 1 to about 100 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

51. The use~~method~~ of claim 42, wherein the therapeutically effective amount is about 10 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

52. The use~~method~~ of claim 42, wherein the therapeutically effective amount is about 30 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

53. The use~~method~~ of claim 42, wherein the therapeutically effective amount is about 100 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

54. The use~~method~~ of claim 42, wherein the therapeutically effective amount is about 200 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

55. The use~~method~~ of claim 42, wherein the therapeutically effective amount is about 300 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

56. The use~~method~~ of claim 42, wherein the therapeutically effective amount is about 400 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

57. The use~~method~~ of claim 42, wherein the therapeutically effective amount is about 600 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

58. The use~~method~~ of claim 42, wherein the therapeutically effective amount is about 800 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

59. The use~~method~~ of claim 42, wherein the therapeutically effective amount is about 1000 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.

60. The use~~method~~ of claim 42, wherein the therapeutically effective amount is about 1200 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.


61. The use~~method~~ of any one of claims 24-60, wherein the medicament to be orally administered ~~compound or a pharmaceutically acceptable salt or prodrug thereof~~ is to be administered once daily.











62. The use~~method~~ of any one of claims 24-60, wherein medicament to be orally administered ~~the compound or a pharmaceutically acceptable salt or prodrug thereof~~ is to be administered twice daily.











63. The use~~method~~ of any one of claims 24-60, wherein the medicament to be orally administered ~~compound or a pharmaceutically acceptable salt or prodrug thereof~~ is to be administered three times daily.











64. The use~~method~~ of any one of claims 24-63, wherein the medicament to be orally administered ~~compound or a pharmaceutically acceptable salt or prodrug thereof~~ is to be administered as an oral dosage form of any one of claims 1-23.













65. A compound selected from:

























	
	
	
	
	










	
	
	
	
	











	
	
	
	
	











	
	
	
	
	
	











	
	
	
	
	
	












	
	
	
	
	











	
	
	
	
	













	
	
	
	
	



	
	
	
	
	

, or a pharmaceutically acceptable salt or prodrug thereof, for use in therapy.